Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-03-20
2009-06-30
Maier, Leigh C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S646000
Reexamination Certificate
active
07553818
ABSTRACT:
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
REFERENCES:
patent: 4513006 (1985-04-01), Maryanoff et al.
patent: 4792569 (1988-12-01), Maryanoff et al.
patent: 4895845 (1990-01-01), Seed
patent: 5242942 (1993-09-01), Costanzo et al.
patent: 5266591 (1993-11-01), Wierzbicki
patent: 5273993 (1993-12-01), Lo et al.
patent: 5498629 (1996-03-01), Costenzo et al.
patent: 5527788 (1996-06-01), Svec et al.
patent: 5543405 (1996-08-01), Keown et al.
patent: 5753693 (1998-05-01), Shank
patent: 5753694 (1998-05-01), Shank
patent: 5795895 (1998-08-01), Anchors
patent: 5900418 (1999-05-01), Viner
patent: 6071537 (2000-06-01), Shank
patent: 6201010 (2001-03-01), Cottrell
patent: 6323236 (2001-11-01), McElroy
patent: 6362220 (2002-03-01), Cottrell
patent: 2004/0002462 (2004-01-01), Najarian
patent: WO 00/50020 (2000-08-01), None
patent: WO 00/76493 (2000-12-01), None
Physicians' Desk Reference (1999) pp. 1053-1054.
Bray et al. (1999), “Current and Potential Drugs for Treatment of Obesity”, Endocrine Reviews 20(6):805-875.
Merck Index, The, an Encyclopedia of Chemicals, Drugs, and Biologicals, Twelfth Edition, Published by Merck Research Laboratories, 1996.
Privitera, (1997), “Topiramate: A New Antiepileptic Drug”, The Annals of Pharmacotherapy, vol. 31, pp. 1164-1173.
Shapira, (2000), “Treatment of Binge-Eating Disorder With Topiramate: A Clinical Case Series”, J. Clin. Psychiatry, 61:5, pp. 368-372.
U.S. Appl. No. 60/139,022, filed Jun. 14, 1999, Najarian.
U.S. Appl. No. 60/178,563, filed Jan. 26, 1000, Najarian.
U.S. Appl. No. 60/181,265, filed Feb. 9, 2000, Najarian.
Physician's Desk Reference, 49thEdition, pp. 2508-2509 (1995).
Bradley et al. (1999), “Bupropion SR with Phentermine for Weight Reduction,”Book of Abstracts, American Psychiactric Association Meeting(distributed to meeting attendees), Washington, D.C. (abstract only).
Bray et al. (2002), “Topiramate Produces Dose-Related Weight Loss,”62ndAnnual American Diabetes Association Meeting, San Francisco.
Carek, et al., (1999) “Current concepts in the pharmacological management of obesity,”Drugs6:883-904.
Coyne (1997), letter regarding Ionamin to the U.S. Food and Drug Administration, printed from http://www.fda.gov/medwatch/safety/1997)/ionami2.htm.
FDC Reports, Inc. (1999), “Appetite Suppression Drugs Excluded by 81 % of Employers—PBMI Survey,”The Green Sheet48(19):3.
Gadde et al. (1999), “Bupropion SR in Obesity: A Rendomized Double-Blind Placebo-Controlled Study,”Obesity Research7(Suppl. 1):51F, Abstract 0136; Annual Meeting of the North American Association for the Study of Obesity, Charlestown, S.C.
Griffen et al., (1998) “The ‘phen-pro’ diet drug combination,” Arch. Intern. Med. 158:1278-1279.
Michelucci et al. (1998), “The Preclinical and Therapeutic Activity of the Novel Anticonvulsant Topiramate,”CNS Drug Reviews4(2):165-186.
Penovich et al. (1994), “Weight Loss in Patients Receiving Topiramate for Intractable Epilepsy,”Neurology44(Suppl. 2), Abstract 309P, 46thAnnual Meeting of the American Academy of Neurology, Washington, D.C.
Potter et al. (1997), “Sustained Weight Loss Associated with 12-Month Topiramate Therapy,”Epilepsia38(Suppl. 8):97; Annual Meeting of the American Epilepsy Society, Boston, MA.
Raritan (2002), “Clinical Development of Topiramate for Obesity Extended to Simplify Dosing, Improve Tolerability,” Johnson & Johnson Pharmaceutical Research & Development, LLC press release, printed from http://www.jnj.com
ews finance/448.htm.
U.S. Food and Drug Administration (1997) “FASTIN (Phentermine HCl) Capsules,”Oct. 1997 Drug Labeling Changes, printed from http://www.fea.gov/medwatch/safety/1997/oct97.htm.
U.S. Food and Drug Administration (1999), “IONAMIN (Phentermine Resin) Capsules,”Feb. 1998 Drug Labeling Changes, printed from http://www.fea.gov/medwatch/safety/1998/feb99.htm.
Weintraub, et al., (1984) “A double-blind clinical trial in weight control,”Arch. Intern. Med. 144:1143-1148.
Zarate (2000), “Antipsychotic Drug Side Effect Issues in Bipolar Manic Patients,”J. Clin Psychiatry61(Suppl. 8):52-61, Derwent.
Maier Leigh C
Mintz Levin Cohn Ferris Glovsky & Popeo P.C.
Vivus Inc.
LandOfFree
Combination therapy for effecting weight loss and treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for effecting weight loss and treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for effecting weight loss and treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4062395